Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 40,400 shares, an increase of 124.4% from the January 15th total of 18,000 shares. Based on an average daily volume of 47,100 shares, the short-interest ratio is currently 0.9 days. Approximately 2.4% of the shares of the company are short sold.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Geode Capital Management LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned 0.59% of Creative Medical Technology as of its most recent SEC filing. Institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Price Performance

Shares of NASDAQ CELZ traded up $0.66 during mid-day trading on Thursday, hitting $4.79. The company had a trading volume of 378,170 shares, compared to its average volume of 75,108. The business’s 50-day simple moving average is $2.62 and its 200-day simple moving average is $3.06. Creative Medical Technology has a 12 month low of $1.96 and a 12 month high of $10.28. The firm has a market cap of $8.38 million, a P/E ratio of -1.25 and a beta of 1.85.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.